Self-blinding citizen science to explore psychedelic microdosing.

Area of Science:

• Psychopharmacology
• Citizen Science
• Psychedelic Research

Background:

• Microdosing psychedelics is an emerging practice with anecdotal reports of enhanced well-being and cognition.
• Potential placebo effects may bias self-reported outcomes in microdosing studies.
• Large-scale, placebo-controlled trials are needed to validate these subjective experiences.

Purpose of the Study:

• To investigate the effects of microdosing psychedelics in a placebo-controlled setting.
• To assess whether observed benefits of microdosing exceed the placebo effect.
• To leverage citizen science for a large-scale psychedelic trial.

Main Methods:

• A self-blinding citizen science initiative with 191 participants undertaking a 4-week microdosing regimen.
• Participants were instructed to incorporate placebo controls into their routine without clinical supervision.
• Psychological outcomes were measured from baseline to the end of the dosing period.

Main Results:

• Significant improvements in psychological outcomes were observed from baseline in both microdose and placebo groups.
• No significant differences in overall psychological outcomes were found between the microdose and placebo groups.
• Small, significant differences in acute and post-acute scales were noted, potentially due to participants breaking the blind.

Conclusions:

• The observed psychological benefits of microdosing psychedelics appear to be attributable to the placebo effect.
• This study, the largest placebo-controlled trial on psychedelics to date, highlights the importance of rigorous controls in psychedelic research.
• Further research should focus on understanding the mechanisms of the placebo effect in psychedelic experiences.